title: Structural constraints for the binding of short peptides to claudin-4 revealed by surface plasmon resonance.
abstract: Claudin family transmembrane proteins play an important role in tight junction structure and function in epithelial cells. Among the 24 isoforms identified in mice and humans, claudin-4 and -3 serve as the receptor for Clostridium perfringens enterotoxin (Cpe). The second extracellular loop (Ecl2) of claudin-4 is responsible for the binding to the C-terminal 30 amino acids of Cpe (Cpe30). To define the structural constraints for the claudin-4/Cpe30 interaction, a surface plasmon resonance (SPR) method was developed. GST fusions with claudin-4 revealed that Ecl2 with the downstream transmembrane domain of claudin-4 reconstituted the basic structural requirement for optimal binding activity to Cpe30, with affinity in the nanomolar range. Two 12-mer peptides selected by phage display against claudin-4-transfected CHO cells and a 12-mer Cpe mutant peptide also showed significant affinity for claudin-4 with this SPR assay, suggesting that a short peptide can establish stable contact with Ecl2 with nanomolar affinity. Alignment of these short peptides unveiled a common Ecl2 binding motif: <XX(Y/W)(X)(3 or 4)Y(Y/X)(L/I)XX>. Whereas the short peptides bound native claudin-4 on transfected CHO cells in pull-down assays, only the larger Cpe30 peptide affected trans-epithelial electrical resistance (TER) in peptide-treated Caco-2BBe monolayers. Importantly, Cpe30 retained its binding to claudin-4 when fused to the C terminus of influenza hemagglutinin, demonstrating that its binding activity can be maintained in a different biochemical context. These studies may help in the design of assays for membrane receptor interactions with soluble ligands, and in applying new targeting ligands to delivering attached "cargo" proteins.
authors.affiliation: Division of Biomedical Sciences, University of California, Riverside, California, USA.
authors.forename: Jun
authors.initials: J
authors.lastname: Ling
authors.forename: Hailing
authors.initials: H
authors.lastname: Liao
authors.forename: Robin
authors.initials: R
authors.lastname: Clark
authors.forename: Mandy Sze Man
authors.initials: MS
authors.lastname: Wong
authors.forename: David D
authors.initials: DD
authors.lastname: Lo
mesh_terms: D020816:Amino Acid Motifs / Q000235:genetics; D000818:Animals; D016466:CHO Cells; D062506:Claudin-4; D003016:Clostridium perfringens / Q000737:chemistry / Q000378:metabolism*; D006224:Cricetinae; D003412:Cricetulus; D004731:Endotoxins / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D006389:Hemagglutinins, Viral / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D006801:Humans; D008565:Membrane Proteins / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D051379:Mice; D010455:Peptides / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D011485:Protein Binding / Q000235:genetics; D011971:Receptors, Immunologic / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D011993:Recombinant Fusion Proteins / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D020349:Surface Plasmon Resonance / Q000379:methods
chemical_list: C568157:CLDN4 protein, human; D062506:Claudin-4; C568158:Cldn4 protein, mouse; D004731:Endotoxins; D006389:Hemagglutinins, Viral; D008565:Membrane Proteins; D010455:Peptides; D011971:Receptors, Immunologic; D011993:Recombinant Fusion Proteins; C048071:endotoxin receptor
references.citation: J Biol Chem. 2008 Jan 4;283(1):268-274
references.pmid: 17977833
references.citation: Biochem Pharmacol. 2008 Apr 15;75(8):1639-48
references.pmid: 18342294
references.citation: Science. 2007 Nov 23;318(5854):1258-65
references.pmid: 17962520
references.citation: Cell Mol Life Sci. 2007 Jan;64(1):17-28
references.pmid: 17115119
references.citation: Biochem Pharmacol. 2007 Mar 15;73(6):824-30
references.pmid: 17169334
references.citation: Oncol Rep. 2006 Oct;16(4):729-34
references.pmid: 16969486
references.citation: Nucleic Acids Res. 2004 Jul 1;32(Web Server issue):W321-6
references.pmid: 15215403
references.citation: Clin Infect Dis. 1997 Sep;25 Suppl 2:S165-7
references.pmid: 9310665
references.citation: Drug Discov Today. 2005 Sep 1;10(17):1145-57
references.pmid: 16182207
references.citation: J Control Release. 2005 Nov 2;108(1):56-62
references.pmid: 16091298
references.citation: Cancer Res. 2005 Nov 1;65(21):9603-6
references.pmid: 16266975
references.citation: Mol Pharmacol. 2005 Mar;67(3):749-56
references.pmid: 15602007
references.citation: Int Immunol. 2004 Jan;16(1):91-9
references.pmid: 14688064
references.citation: Infect Immun. 2007 May;75(5):2381-90
references.pmid: 17307943
references.citation: J Cell Biol. 1999 Oct 4;147(1):195-204
references.pmid: 10508866
references.citation: FEBS Lett. 2000 Jul 7;476(3):258-61
references.pmid: 10913624
references.citation: J Pharmacol Exp Ther. 2005 Aug;314(2):789-95
references.pmid: 15870390
references.citation: J Cell Biol. 1997 Mar 24;136(6):1239-47
references.pmid: 9087440
references.citation: J Membr Biol. 2004 May 1;199(1):29-38
references.pmid: 15366421
references.citation: Cell Commun Adhes. 2006 May-Jun;13(3):127-38
references.pmid: 16798613
references.citation: J Biol Chem. 2005 Dec 23;280(51):42375-82
references.pmid: 16236711
references.citation: Gastroenterology. 2001 Feb;120(2):411-22
references.pmid: 11159882
references.citation: Science. 2007 Nov 23;318(5854):1266-73
references.pmid: 17962519